Table 3. PK Parameters of LEN Following Subcutaneous Administration of LEN in an Aqueous Suspension Formulation to Male Beagle Dogs^abcd.

group ID	dose (mg/kg)b	dose volume (mL/kg)	AUC0–72 h (μM·h)	AUC0–672 h (μM·h)	AUClast (μM·h)	AUCinf (μM·h)	Cmax (μM)	Tmax (h)	t1/2 (h)	% of AUCinf on day 3	% of AUCinf on day 28	mean F%d
11	3	0.03	3.0 ± 2.1	18.6 ± 9.0	25.4 ± 7.5	28.0 ± 6.4	0.056 ± 0.037	72 ± 83	525 ± 147	11	66	49 ± 11
12	6	0.06	20.8 ± 7.4	117 ± 37	128 ± 41	129 ± 42	0.410 ± 0.141	40 ± 28	322 ± 51	16	91	114 ± 37
13	6	0.03 × 2c	18.8 ± 2.4	85.0 ± 7.0	88.4 ± 6.2	88.9 ± 6.2	0.417 ± 0.014	64 ± 28	174 ± 38	21	96	78 ± 5
14	6	0.03	6.6 ± 3.4	63.9 ± 27.3	75.9 ± 34.6	79.1 ± 32.2	0.175 ± 0.068	96 ± 63	354 ± 329	8	96	70 ± 28
15	30	0.30	145 ± 9	496 ± 49	497 ± 51	497 ± 51	2.96 ± 0.30	40 ± 14	66 ± 5	29	100	88 ± 9
16	100	1.0	340 ± 76	1336 ± 504	1356 ± 500	1357 ± 500	7.24 ± 1.28	32 ± 14	94 ± 59	25	100	72 ± 26

^aValues are the mean ± SD from 3 animals. AUC_0–72 h = 3-day AUC; AUC_0–672 h = 28-day AUC; SD = standard deviation.

^bFormulation concentration at 100 mg/mL LEN (groups 11–13; 15, 16) and at 200 mg/mL LEN (group 14).

^cTwo injections, each at a distinct site.

^dF% = Total fraction dose released = 100 × dose-normalized SC AUC_inf-to-IV AUC_inf ratio.